Published in
BioMed Central, Breast Cancer Research, 1(21), 2019
DOI: 10.1186/s13058-019-1154-8
Links
Tools
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Journal article published in 2019 by
Yan Xing,
Nancy U. Lin,
Matthew A. Maurer,
Huiqin Chen,
Armeen Mahvash 
,
Aysegul Sahin,
Argun Akcakanat ,
Yisheng Li,
Vandana Abramson,
Jennifer Litton,
Mariana Chavez-Macgregor,
Vicente Valero,
Sarina A. Piha-Paul ,
David Hong,
Kim-Anh Do
and other authors.
,
Aysegul Sahin,
Argun Akcakanat ,
Yisheng Li,
Vandana Abramson,
Jennifer Litton,
Mariana Chavez-Macgregor,
Vicente Valero,
Sarina A. Piha-Paul ,
David Hong,
Kim-Anh Do
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 